Welcome to National Black Church Initiative
And The American Clinical Health Disparities Commission's Clinical Trial Portal
NBCI is ushering in a new era of broadened engagement of Black and Latino communities in clinical trials. Particularly given the unethical and illegal behaviors involved with the Tuskegee Experiment and the intentional absence or lack of critical information for the involved subjects by governmental officials, the NBCI comprehensive approach utilizes important lessons learned from this historic medical abuse and ALL others experienced within Black and Latino communities for generating robust communication, demonstration, and education strategies toward substantially improving clinical trial participation.
The goal of the NBCI Interactive Clinical Trials Portal is to improve the health outcomes of the African American community by making African Americans aware of the critical features, benefits, and challenges of clinical trials. This study website provides scientific facts that may positively influence African Americans' feelings about their participation in clinical trials. Additionally, this website attempts to provide an understanding of the complex relationship African Americans have historically had with clinical trials.
Faith & Medicine l Primary Care
The National Black Church Initiative (NBCI) is a coalition of 150,000 African-American and Latino churches with a population of 27.7 million covering all therapeutic demographic groups working to eradicate racial disparities in healthcare, clinical trials, technology, education, housing, and the environment.
Therapeutic areas of interest to the African American and Latino communities: 9 pillars of NBCI Clinical Research Approach
- Cardiovascular Diseases
- Cancer: (Liver/Kidney/Lung ...etc)
- Diabetes
- Blood Diseases
- Genetic Disease ( Sickle Cell)
- Mental health
- Acess to Care/ lifestyles/ Selfcare
- Collection of Health Data
- Rare Diseases
FDA to require diversity plan for clinical trials
US regulatory agency makes ‘big change’ to increase the number of participants from under-represented groups in drug testing.
The US Food and Drug Administration (FDA) will soon require researchers and companies seeking approval for late-stage clinical trials to submit a plan for ensuring diversity among trial participants.
Treatment of Rare Anemias Shifting Rapidly
A wave of new therapies is starting to reshape the treatment landscape for people with rare anemias, but the authors of a new review also caution that more research is needed to better understand which therapies are right for which patients.
Read More